Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01069510
Other study ID # eIRB 5845
Secondary ID K23HL093024-01A1
Status Completed
Phase Phase 2
First received
Last updated
Start date February 2010
Est. completion date March 2017

Study information

Verified date July 2019
Source Oregon Health and Science University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to see if the study drug called spironolactone reduces fibrous (stiffening) in heart muscle tissue and improves heart function. Subjects from the study titled "Heart Failure in Congenital Heart Disease: the role of myocardial fibrosis" who have evidence of heart dysfunction and/or evidence of fibrosis (stiffening) in the heart muscle will be asked to take part in this study.


Description:

This study will include randomizing the subject to receive the study drug or placebo. Randomization will occur during visit 1.

Visit 1 will include the following:

- Subjects will answer questions about how well they can breathe.

- An MRI. Dye called gadolinium will be injected into the subject's vein.

- They will go to the Oregon Clinical and Translational Research Institute where 2 tablespoons of blood will be drawn from an intravenous (IV) catheter (tube).

- They will do a 6 minute walk test..

- They will also have an echocardiogram, which is a test that looks at the movement of the subject's heart. A technician will place a cool jelly on their chest and use a small wand to take pictures through the skin.

Subjects' will also have visits 3-6 weeks, 3, 6, 9 months, and 12 months after randomization. Visits 2-5 will include the following:

- They will go to the Oregon Clinical and Translational Research Institute where 1/2 tablespoon of blood will be drawn.

- They will do a 6 minute walk test. During this test, they will walk back and forth in a hallway. The goal is to walk as far as possible for 6 minutes. Subjects will probably get out of breath or become exhausted. If they do, they can slow down, stop, or rest as they need to. Blood pressure will be taken before the walk.

- They will have a health review at 6 months.

Visit 6 will be identical to visit 1 and include the following:

- Subjects will answer questions about how well they can breathe.

- An MRI. Dye called gadolinium will be injected into the subject's vein.

- They will go to the Oregon Clinical and Translational Research Institute where 2 tablespoons of blood will be drawn from an intravenous (IV) catheter (tube).

- They will do a 6 minute walk test..

- They will also have an echocardiogram, which is a test that looks at the movement of the subject's heart. A technician will place a cool jelly on their chest and use a small wand to take pictures through the skin.

The investigators will compare the study drug, called spironolactone, to placebo with regard to any changes in heart stiffening and function of the heart.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date March 2017
Est. primary completion date June 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

1. Fibrosis index =29%, or

2. Evidence of cardiovascular dysfunction including any of the following:

- Systemic ejection fraction <55%,

- NYHA 2-3

- 6-minute walk distance <500 m.

3. Completion of Visit 1 of the study Heart Failure in Congenital Heart Disease: the role of myocardial fibrosis" (eIRB # 3665) including meeting all inclusion for that study (Aged 18-80, Known congenital heart disease).

4. Tetralogy of Fallot, cyanotic congenital heart disease, or a systemic right ventricle.

Exclusion Criteria:

1. Patient currently taking spironolactone or previously taking spironolactone within the last 6 months.

2. Serum potassium =5.0 mmol/L at the initial visit, if not taking potassium supplements. Patients will be eligible if a repeat potassium is <5.0 mmol/L after potassium supplements have been discontinued.

3. Moderate/severe systemic atrioventricular valve regurgitation,

4. Likely to undergo cardiac surgery, pacemaker implantation, or possible transplantation within one year (all self-reported),

5. Unwilling to commit to return visits including mandatory blood draws for potassium,

6. Renal insufficiency (estimated creatinine clearance < 30 ml/min/1.73m2),

7. Positive urine pregnancy test.

8. Any contraindication to MRI.

Study Design


Intervention

Drug:
Spironolactone 25mg
Spironolactone 25 mg daily for 12 months
Other:
Placebo
Placebo daily for 12 months

Locations

Country Name City State
United States Oregon Health & Science University Portland Oregon

Sponsors (3)

Lead Sponsor Collaborator
Oregon Health and Science University National Heart, Lung, and Blood Institute (NHLBI), Oregon Clinical and Translational Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Extracellular Volume Fraction extracellular volume fraction measured by T1 mapping with MRI 12 month
Secondary 6-minute Walk Distance distance walked recorded in meters after 6 minutes on flat ground 12 month
Secondary Procollagen 3 NT Peptide 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy